Lilly Declares $1.73 Q3 Dividend as Market Cap Tops $1 Trillion
LLY•Lilly’s board declared a third-quarter 2026 dividend of $1.73 per share payable September 10 to holders of record August 14, 2026. The company surpassed a $1 trillion market valuation after Q2 revenue grew 55.5% year-over-year, driven by $8.66 billion in Mounjaro sales and raising 2026 revenue guidance to $82–85 billion.
1. Q3 2026 Dividend Declared
Lilly’s board declared a Q3 2026 dividend of $1.73 per share on outstanding common stock. Shareholders of record as of August 14, 2026 will receive the dividend on September 10, 2026.
2. Market Cap Surpasses $1 Trillion
Following its Q2 report, Lilly became the first healthcare firm to exceed a $1 trillion market valuation, driven by revenue of $19.80 billion, a 55.5% increase year-over-year.
3. Mounjaro and Zepbound Performance
Mounjaro contributed $8.66 billion to quarterly sales, while Zepbound also recorded rapid uptake, reinforcing Lilly’s leadership in the weight loss market.
4. Pricing and Competitive Landscape
Realized prices declined 13% in Q1 after Mounjaro entered China’s National Reimbursement Drug List, weighing on international margins as Pfizer and Novo Nordisk ramp up obesity treatments.
